Advances in cardiac processing software.

Semin Nucl Med

Icahn School of Medicine at Mt. Sinai, Division of Nuclear Medicine, Department of Radiology, Mt. Sinai St. Luke's and Roosevelt Hospitals, New York, NY. Electronic address:

Published: July 2014

New software methods that incorporate iterative reconstruction, resolution recovery, and noise compensation now provide the ability to maintain or improve myocardial perfusion SPECT image quality with conventional sodium iodide cameras. Despite lower image counting statistics associated with significantly decreased injected radiopharmaceutical doses or shortened acquisition times or both, image quality is preserved or even improved compared with conventional processing methods. The ability to prescribe a desired myocardial count density by preselecting a SPECT acquisition time now avoids additional patient radiation exposure associated with "weight-based" dosing. More recent advancements, including temporal correlation among the gated perfusion frames and higher resolution SPECT acquisitions, hold promise to further improve image quality and diagnostic accuracy. Phase analysis of gated perfusion SPECT provides the ability to assess cardiac dyssynchrony and to select those patients who will most benefit from resynchronization therapy. In combination with the higher counting statistics afforded by the new solid-state dedicated cardiac cameras, these software advancements allow for even further decreased patient radiation doses or acquisition times or both. List-mode software allows for refinement of myocardial perfusion SPECT by interrogating particular data from selected cardiac cycles. Rejection of frames degraded by arrhythmic cardiac cycles or excessive extracardiac uptake can be excluded for reconstruction. Respiratory gating, which diminishes cardiac motion and potentially decreases diaphragmatic attenuation, has been demonstrated to improve diagnostic specificity. With high-count first-pass list-mode acquisitions at rest and during pharmacologic vasodilatation, it may be possible to measure global and regional myocardial perfusion reserve to more accurately diagnose coronary artery disease and avoid false-negative studies owing to balanced ischemia.

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semnuclmed.2014.04.001DOI Listing

Publication Analysis

Top Keywords

myocardial perfusion
12
perfusion spect
12
image quality
12
counting statistics
8
acquisition times
8
patient radiation
8
gated perfusion
8
cardiac cycles
8
perfusion
5
spect
5

Similar Publications

Background: Normothermic ex situ heart perfusion (ESHP) has emerged as a valid modality for advanced cardiac allograft preservation and conditioning prior to transplantation though myocardial function declines gradually during ESHP thus limiting its potential for expanding the donor pool. Recently, the utilization of dialysis has been shown to preserve myocardial and coronary vasomotor function. Herein, we sought to determine the changes in myocardial metabolism that could support this improvement.

View Article and Find Full Text PDF

Flurpiridaz F 18: First Approval.

Am J Cardiovasc Drugs

January 2025

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Flurpiridaz F 18 (FLYRCADO™) is an intravenous (IV) radioactive diagnostic drug being developed by GE Healthcare and Lantheus Medical Imaging for use in positron emission tomography (PET) myocardial perfusion imaging (MPI) to detect coronary artery disease (CAD). In September 2024, flurpiridaz F 18 was approved in the USA for PET MPI under rest or stress (pharmacologic or exercise) in adult patients with known or suspected CAD to evaluate for myocardial ischemia and infarction. This article summarizes the milestones in the development of flurpiridaz F 18 leading to this first approval for use in PET MPI in adult patients to evaluate for myocardial ischemia and infarction.

View Article and Find Full Text PDF

The electrophysiological mechanisms underlying melatonin's actions and the electrophysiological consequences of superimposed therapeutic hypothermia (TH) in preventing cardiac ischemia-reperfusion (IR) injury-induced arrhythmias remain largely unknown. This study aimed to unveil these issues using acute IR-injured hearts. Rabbits were divided into heart failure (HF), HF+melatonin, control, and control+melatonin groups.

View Article and Find Full Text PDF

TLR4 Inhibition Attenuated LPS-Induced Proinflammatory Signaling and Cytokine Release in Mouse Hearts and Cardiomyocytes.

Immun Inflamm Dis

January 2025

Division of Physiology, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.

Background: Sepsis is associated with myocardial injury and early mortality. The innate immune receptor Toll-like receptor 4 (TLR4) can recognize pathogen-associated-molecular-patterns (PAMPs) and damage-associated molecular patterns (DAMPs); the latter are released during tissue injury. We hypothesized that TLR4 inhibition reduces proinflammatory signaling and cytokine release in: (1) LPS or Escherichia coli-treated isolated mouse heart; (2) LPS-treated mouse primary adult cardiomyocytes; and (3) the isolated heart during ischemia-reperfusion.

View Article and Find Full Text PDF

Refractory angina pectoris (RAP) is a clinical syndrome characterized by persistent chest pain caused by myocardial ischemia that is unresponsive to optimal pharmacological therapy and revascularization procedures. Spinal cord stimulation (SCS) has emerged as a promising therapeutic option for managing RAP, offering significant symptom relief and improved quality of life. A systematic literature review was conducted to evaluate the clinical effectiveness, mechanisms of action, and safety profile of SCS in treating RAP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!